SELNET clinical practice guidelines for soft tissue sarcoma and GIST

Blay, J. Y.; Hindi, N.; Bollard, J.; Aguiar, S.; Angel, M.; Araya, B.; Badilla, R.; Bernabeu, D.; Campos, F.; Caro-Sánchez, C. H. S.; Carvajal, B.; Carvajal Montoya, A.; Casavilca-Zambrano, S.; Castro-Oliden, V.; Chacón, M.; Clara, M.; Collini, P.; Correa Genoroso, R.; Costa, F. D.; Cuellar, M.; dei Tos, A. P.; Dominguez Malagon, H. R.; Donati, D.; Dufresne, A.; Eriksson, M.; Farias-Loza, M.; Fernandez, P.; Frezza, A. M.; Frisoni, T.; Garcia-Ortega, D. Y.; Gelderblom, H.; Gouin, F.; Gómez-Mateo, M. C.; Gronchi, A.; Haro, J.; Huanca, L.; Jimenez, N.; Karanian, M.; Kasper, B.; Lopes David, B. B.; Lopez-Pousa, A.; Lutter, G.; Martinez-Said, H.; Martinez-Tlahuel, J.; Mello, C. A.; Morales Pérez, J. M.; Moura David, S.; Nascimento, A. G.; Ortiz-Cruz, E. J.; Palmerini, E.; Patel, S.; Pfluger, Y.; Provenzano, S.; Righi, A.; Rodriguez, A.; Salas, R.; Santos, T. T. G.; Scotlandi, K.; Soule, T.; Stacchiotti, S.; Valverde, C.; Waisberg, F.; Zamora Estrada, E.; Martin-Broto, J.

doi:10.1016/j.ctrv.2021.102312

Soft tissue sarcoma (STS) is a heterogeneous group of neoplasms, encompassing >80 different histologic subtypes. Approximately three quarter of sarcoma arise from soft-tissue, about 15% are gastrointestinal stromal tumours (GISTs) and bone sarcoma represent the remaining 10%. The current guidelines will focus on soft-tissue and GIST, excluding Kaposi sarcoma and non-pleomorphic rhabdomyosarcoma

Blay, J., Hindi, N., Bollard, J., Aguiar, S., Angel, M., Araya, B., et al. (2022). SELNET clinical practice guidelines for soft tissue sarcoma and GIST. CANCER TREATMENT REVIEWS, 102, 1-10 [10.1016/j.ctrv.2021.102312].